USD 16.4 billion
Antibody Production Market Size, Share, Growth Analysis, By Product (Instruments, Chromatography Systems), By Process (Upstream Processing, Downstream Processing), By Type (Polyclonal Antibody, Monoclonal Antibody), By End Use, By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35H2171 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|Tables:
61
|Figures:
75
Antibody Production Market Insights
Antibody Production Market size was valued at USD 18.52 Billion in 2023 and is poised to grow from USD 20.91 Billion in 2024 to USD 55.19 Billion by 2032, growing at a CAGR of 12.9% during the forecast period (2025-2032).
The purpose of the antibody production market is to meet the growing demand for antibodies that can be used in the development of targeted therapies, diagnostics, and vaccines. With the advancements in biotechnology and the increasing understanding of diseases at the molecular level, there is a rising need for specific and effective antibodies. These antibodies are essential tools in studying disease mechanisms, identifying biomarkers, and developing personalized medicine approaches. A key driving factor in the antibody production market is the increasing prevalence of chronic and infectious diseases, which has fueled the demand for targeted therapies and diagnostics. Antibodies have shown promising results in treating diseases such as cancer, autoimmune disorders, and infectious diseases. The growing focus on precision medicine and personalized treatment approaches has further contributed to the market's growth. Despite these challenges, there are several opportunities in the antibody production market.
Technological advancements, such as the development of recombinant DNA technology and high-throughput screening methods, have improved the efficiency and scalability of antibody production. The global antibody production market serves a vital role in the healthcare and pharmaceutical industries by providing essential tools for diagnostics, therapeutics, and research. The market's growth is driven by the increasing demand for targeted therapies, diagnostics, and the pursuit of personalized medicine approaches. While challenges exist, technological advancements and evolving healthcare needs create opportunities for innovation and expansion in the antibody production market.
US Antibody Production Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Monoclonal Antibody
Fastest Growth
Monoclonal Antibody
Growth Rate
12.9% CAGR
Global Antibody Production Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Antibody Production Market Segmental Analysis
Global Antibody Production Market is segmented by product, process, type, end use and region. Based on product, the market is segmented into instruments, chromatography systems, filtration systems, consumables and software. Based on process, the market is segmented into upstream processing and downstream processing. Based on type, the market is segmented into polyclonal antibody and monoclonal antibody. Based on end use, the market is segmented into pharmaceutical and biotechnology companies, research laboratories and cros and cdmos. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Analysis by Type
In 2022, the monoclonal antibody segment is projected to dominate the antibody production market, accounting for a significant revenue share of 63.25%. This segment is also expected to exhibit a higher compound annual growth rate (CAGR) of 13.58% during the period of 2023-2030. The growth of this segment can be attributed to the increasing investments in research on monoclonal antibodies and the introduction of novel antibody-based products. A notable example is the investment made by Eli Lilly, a US-based pharmaceutical company, in March 2023. They have allocated nearly USD 1 billion to establish a monoclonal antibody manufacturing plant in Ireland, with production expected to commence by 2026. This investment indicates the significant focus and potential of the monoclonal antibody segment in the market.
The polyclonal antibody segment is expected to experience substantial growth in the forecast period. This is primarily due to several advantages associated with polyclonal antibodies, including a smoother production process and their availability at a lower cost. The growing demand for diagnostic tests for prevalent diseases further contributes to the growth of this segment. Moreover, advancements in technology and techniques for polyclonal antibody production, such as recombinant DNA technology and transgenic animal models, are likely to fuel the expansion of this segment. Notably, polyclonal antibodies can be produced more quickly and cost-effectively compared to monoclonal antibodies, as they do not require the complex cell culture and screening processes involved in monoclonal antibody production. This makes polyclonal antibodies an attractive option in terms of efficiency and cost-effectiveness for various applications in the antibody production market.
Analysis by Process
In 2022, The downstream segment emerged as the dominant sector in the antibody production market capturing a significant market share of 67.04%. This segment is expected to exhibit a faster compound annual growth rate (CAGR) of 13.48% from 2023 to 2030. The downstream process plays a crucial role in ensuring the quality, safety, efficacy, purity, and identity of antibodies. It encompasses various steps and technologies that contribute to efficient bio-manufacturing and enable continuous innovation. Technological advancements have significantly improved the downstream process, with the introduction of single-use sensors, membrane chromatography technology, remote monitoring, and data analytics. These advancements enhance operational efficiency, increase productivity, and improve product quality. For instance, in March 2019, GE Healthcare and Amgen collaborated on a digital data exchange program to explore advancements in bio-manufacturing and better understand raw material variability. This collaboration reflects the industry's commitment to leveraging technology to optimize the downstream process and enhance overall antibody production capabilities.
The upstream process segment is projected to experience substantial growth in the forecast period. This can be attributed to significant investments and advancements in production infrastructure by various manufacturers. Leading companies are incorporating cutting-edge bioreactors into the upstream process to ensure the delivery of high-quality end-products. For instance, on April 18, 2023, Cytiva (part of Danaher) launched the X-platform single-use bioreactors, which are designed to enhance process efficiency in upstream bioprocessing operations. The versatile X-platform is capable of producing cell and gene therapies, protein-based drugs (including monoclonal antibodies), and viral vectors. These advancements in upstream technologies not only enable improved production efficiency but also support the development of advanced therapies and expand the capabilities of antibody production.
Global Antibody Production Market By Type
To get detailed analysis on other segments, Request For Free Sample Report
Antibody Production Market Regional Insights
In 2022, North America emerged as the leading region for the antibody production market, capturing the largest revenue share of 38.29%. This can be attributed to the presence of prominent biopharmaceutical and biotechnology companies in the United States and Canada. The region's robust healthcare infrastructure, along with substantial investments in drug discovery and research, contributes to the market's growth. The adoption of biopharmaceuticals, including antibodies, is on the rise in North America due to their efficacy, specificity, and safety. These factors drive the demand for antibody production as they are increasingly utilized in the treatment of various diseases. Furthermore, the integration of advanced technologies, such as artificial intelligence (AI) in the drug development process, is gaining momentum. Pharmaceutical companies are investing significantly in AI technology, which accelerates drug discovery and reduces costs. This technological advancement further propels the growth of the antibody production market in North America.
Asia Pacific is projected to exhibit the fastest compound annual growth rate (CAGR) of 16.14% from 2023 to 2030. The region presents untapped opportunities for market expansion. Factors such as increasing investments in research and development activities, growing demand for therapeutics and diagnostics, and a rising aging population contribute to the market's growth in Asia Pacific. Moreover, the prevalence of chronic diseases, including cancer, autoimmune disorders, and infectious diseases, is on the rise in the region. This drives the demand for antibody-based therapies and diagnostics. As a result, the Asia Pacific region holds significant potential for market growth in the antibody production sector.
Global Antibody Production Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Antibody Production Market Dynamics
Antibody Production Market Drivers
Increasing Demand for Antibody-Based Therapeutics
- The growing prevalence of chronic diseases and the rising adoption of targeted therapies have led to an increased demand for antibody-based therapeutics. Antibodies offer specificity and efficacy in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. For example, the development and utilization of monoclonal antibodies (mAbs) have revolutionized the treatment landscape, with several blockbuster drugs being antibody-based therapies.
Advancements in Biotechnology and Biopharmaceutical Research
- Continuous advancements in biotechnology and biopharmaceutical research have accelerated antibody production processes and improved product quality. Technological innovations, such as genetic engineering, cell culture techniques, and high-throughput screening methods, have facilitated the development of novel antibody-based products. These advancements have resulted in increased efficiency, scalability, and cost-effectiveness of antibody production.
Antibody Production Market Restraints
High Development and Production Costs
- The development and production of antibodies involve complex processes, extensive research and development efforts, and large-scale manufacturing facilities. These factors contribute to high costs associated with antibody production, which can be a significant restraint, particularly for small and medium-sized companies. The cost-intensive nature of antibody production limits the accessibility and affordability of antibody-based therapies, posing a challenge to market growth.
Stringent Regulatory Requirements
- The antibody production market is subject to stringent regulatory requirements imposed by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with these regulations is crucial to ensure the safety, quality, and efficacy of antibody-based products. However, the complex regulatory landscape and rigorous approval processes can pose challenges for market players, leading to delays in product development and commercialization.
Request Free Customization of this report to help us to meet your business objectives.
Antibody Production Market Competitive Landscape
The global antibody production market is highly dynamic and characterized by intense competition among key players. The market is dominated by established biopharmaceutical companies, contract research organizations (CROs), and academic institutions with significant expertise and resources in antibody production. To gain a competitive edge, companies in the antibody production market are investing heavily in research and development activities to discover and develop new antibodies with enhanced therapeutic efficacy and improved safety profiles. They are also focusing on expanding their production capacities and optimizing manufacturing processes to meet the growing demand for antibodies. Partnerships, collaborations, and strategic alliances are common strategies adopted by key players to strengthen their market position and broaden their product portfolios. For example, in 2022, AstraZeneca plc (United Kingdom) and Regeneron Pharmaceuticals Inc. (United States) entered into a collaboration to develop and commercialize novel antibody-based therapeutics.
Top Player’s Company Profiles
- Roche (Switzerland)
- Genmab (Denmark)
- Amgen (US)
- Biogen (US)
- Johnson & Johnson (US)
- AbbVie (US)
- AstraZeneca (UK)
- Novartis (Switzerland)
- Pfizer (US)
- Sanofi (France)
- Merck & Co. (US)
- Gilead Sciences (US)
- Celgene (US)
- BioMarin Pharmaceutical (US)
- Shire (Ireland)
- Alexion Pharmaceuticals (US)
- Teva Pharmaceuticals (Israel)
- Allergan (US)
- Bristol Myers Squibb (US)
- Novo Nordisk (Denmark)
Recent Developments
- Amgen gave the public good news in November 2023 when they released the Phase 3 findings for AMG 520. When compared to conventional chemotherapy, this bispecific antibody that targets both EGFR and VEGFR2 significantly improved progression-free survival (PFS). The benefits of AMG 520 in the treatment of patients with metastatic colorectal cancer that is KRAS wild type were particularly underlined in the study.
- AstraZeneca and Daiichi Sankyo joined forces on an innovative initiative in October 2023. Together, they are developing novel cancer therapies known as antibody-drug conjugates (ADCs). AstraZeneca is an expert in ADC technology, and Daiichi Sankyo is a master at creating cancer-specific pharmaceuticals. The medical community is taking notice of this partnership.
- In February 2023, Thermo Fisher Scientific launched its new CHO Cell Line, CHO-S5, which is designed for the production of high-quality monoclonal antibodies.
Antibody Production Key Market Trends
- Increasing Focus on Personalized Medicine: The concept of personalized medicine is gaining traction in the healthcare industry. Antibody production is aligned with this trend as it enables the development of targeted therapies tailored to individual patients. Advancements in genomic and proteomic technologies have facilitated the identification of specific disease markers, allowing the design and production of antibodies targeting these markers, thereby driving the trend towards personalized medicine.
- Rising Adoption of Biosimilars: Biosimilars are biological products that are highly similar to existing approved reference biologic drugs. The increasing demand for cost-effective treatment options has led to the development and adoption of biosimilar antibodies. As patents for some blockbuster biologic drugs expire, the market is witnessing a rise in biosimilar antibody production. This trend promotes competition, expands market opportunities, and enhances accessibility to antibody-based therapies.
Antibody Production Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global antibody production market analysis, the increasing prevalence of chronic diseases, coupled with advancements in biotechnology, and rising demand for personalized medicine are the key growth drivers. The market is driven by the growing need for effective therapies and diagnostics for diseases like cancer, autoimmune disorders, and infectious diseases. The market analysis of the global antibody production market provides valuable insights into the current state of the industry, its drivers, restraints, challenges, and opportunities. It serves as a guide for market participants, investors, and stakeholders to make informed decisions and capitalize on the growing demand for antibodies in healthcare and biopharmaceutical applications. The market is driven by the growing need for effective therapies and diagnostics for diseases like cancer, autoimmune disorders, and infectious diseases. The market analysis of the global antibody production market provides valuable insights into the current state of the industry, its drivers, restraints, challenges, and opportunities. It serves as a guide for market participants, investors, and stakeholders to make informed decisions and capitalize on the growing demand for antibodies in healthcare and biopharmaceutical applications.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 16.4 billion |
| Market size value in 2031 | USD 48.88 billion |
| Growth Rate | 12.9% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Antibody Production Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Antibody Production Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Antibody Production Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Antibody Production Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Antibody Production Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Antibody Production Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
